Announcements, Videos & Industry News
AZ have announced that they are closer to Lynparza (olaparib) being licensed for the treatment of breast cancer. Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy. This is the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.
Steve Jackson has been awarded the UK GSN Medal 2017 for his contributions to the field of genome stability and particularly for the realisation of the therapeutic potential of targeting the DDR.
A paper by Forment et al. describes a genetic screening approach combining chemical mutagenesis and next-generation sequencing in mouse haploid cells as a powerful tool to identify mammalian genetic interactions.
On 29 September 2016 Stephen (Steve) Jackson, Professor of Biology at the University of Cambridge (UK), received the 2016 Dr A.H. Heineken Prize for Medicine for his fundamental research into DNA repair in human cells and for the successful application of knowledge of that process in the development of new cancer drugs.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
In a feature article in Research Horizons, Cambridge University's research magazine, Steve and Eugenia Piddini talk about the challenges of their "counterintuitive" approaches to develop cancer therapies
In a paper by Balmus et al., the authors report that Paxx/Xlf double-knockout mice display embryonic lethality associated with genomic instability, cell death in the central nervous system, and an almost complete block in lymphogenesis, phenotypes that closely resemble those of Xrcc4−/− and Lig4−/− mice.
Repair of single-ended DNA double-strand breaks (seDSBs) by homologous recombination (HR) requires the generation of a 3′ single-strand DNA overhang by exonuclease activities in a process called DNA resection. However.....
A new paper, published in Cell Reports, demonstrates that PAXX and XLF (paralogs of the nonhomologous endjoining factor XRCC4) have distinct roles during V(D)J recombination. V(D)J recombination is the process by which T cells and B cells randomly assemble different gene segments – known as variable (V), diversity (D) and joining (J) genes – in order to generate unique receptors (known as antigen receptors) that can collectively recognize many different types of molecule. PAXX and XLF are required to join broken DNA ends generated during antigen receptor gene assembly. This work was the result of a collaboration between our lab and that of Ludovic Deriano at the Pasteur Institute.
Watch a new video from the Gurdon Institute where Steve describes his research on DNA repair and the ground-breaking work that led to the cancer killing drug olaparib/Lynparza
Three papers were published last month describing a small molecule inhibitor that hypersensitizes tumour cells to DNA-damaging agents (http://bit.ly/2aTZpfA); insights into the mechanism of vascular aging (http://bit.ly/2auaFkJ); and how global genome nucleotide excision repair (GG-NER) is organised into distinct domains (http://bit.ly/2aG6fFE).
Postdoc Christine Schmidt is co-corresponding author on a paper in ACS Nano. In this study the authors have used rolled-up nanomembranes to study how 3D spatial confinement affects the way single cells grow and divide.
Steve has won the University of Cambridge Vice Chancellor's inaugural Impact Award for the School of Biological Sciences, in recognition of his work on the DNA damage response, leading to the development of PARP inhibitors, a new class of anti-cancer drugs.
Steve Jackson has been awarded the Dr. A.H. Heineken Prize for Medicine by the Royal Netherlands Academy of Arts and Science for his "fundamental research into DNA repair in human cells and for the successful application of knowledge of that process in the development of new cancer drugs".
A novel highly efficient gene edting technique is described by Chiang et al., in Scientific Reports. This method combines an All-In-One Cas9D10A nickase vector with FACS enrichment, high-throughput genotypic and phenotypic clonal screening strategies to generate isogenic knockouts and knock-ins highly efficiently, with minimal off-target effects.